Clinical trials: Second-Line
Advanced Breast Cancer
Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer
This is a phase 2, open-label, multicenter, 2-arm study of bosutinib administered in combination with exemestane versus exemestane alone. This is a 2-part study consisting of a safety lead-in phase and randomized phase 2 portion.
- Trial name
- NCT00793546
- Testing
- Bosutinib, exemestane
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 42 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma, Immune Checkpoint Inhibitors
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
Nowadays, there are few second-line treatment options for advanced hepatocellular carcinoma (HCC). In order to further improve the efficacy of second-line treatment for advanced HCC, we plan to conduct a phase II clinical study…
- Conditions
- Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
- Trial name
- NCT06446154
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Lymphoma, Non-Hodgkin
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- TRANSFORM (NCT03575351)
- Testing
- Standard of Care, JCAR017
- Where
- 54 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- Celgene
NSCLC
Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)
The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.
- Trial name
- NCT03416231
- Testing
- Apatinib, Docetaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
Gastric Cancer, Gastroesophageal Junction Cancer
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing…
- Trial name
- NCT06346392
- Testing
- AZD0901, Ramucirumab+ paclitaxel, Paclitaxel
- Where
- 158 sites in United States, Brazil and 17 more
- Volunteers
- 594 people
- Sponsor
- AstraZeneca
Nasopharyngeal Carcinoma
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed…
- Trial name
- NCT03866967
- Testing
- AK105
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Akeso
Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer
FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)
The goal of this clinical trial is to test whether adding targeted radiation plus cadonilimab immunotherapy to standard second-line chemo works better for adults with colorectal cancer only spread to the peritoneum, and check how…
- Conditions
- Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy
- Trial name
- TORCH-PM02 (NCT07815834)
- Testing
- Second-Line Chemotherapy, Radiation Therapy, Cadonilimab (AK104)
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Fudan University
Pancreatic Neoplasms
Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer
The purpose of this study is to see the effect of PEP02 in the treatment of metastatic pancreatic cancer.
- Trial name
- NCT00813163
- Testing
- PEP02
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 41 people
- Sponsor
- PharmaEngine
Metastatic Pancreatic Adenocarcinoma
Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma
This trial will assess the safety and tolerability of Pepinemab in combination with Avelumab in patients with metastatic pancreatic adenocarcinoma that has progressed after first line chemotherapy.
- Trial name
- NCT05102721
- Testing
- Avelumab and Pepinemab
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Vaccinex Inc.
Urologic Neoplasms, Carcinoma, Transitional Cell
2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
To investigate efficacy and safety of 2nd line GEM monotherapy after CDDP regimen for patients with transitional cell carcinoma of urothelium
- Trial name
- NCT00191971
- Testing
- Gemcitabine
- Where
- 12 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Eli Lilly and Company
Neuroendocrine Carcinomas
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer
Poorly differentiated neuroendocrine carcinomas (NEC) are a sub-group of aggressive neuroendocrine neoplasms (NEN). The most common primary sites are broncho-pulmonary and digestive.
- Trial name
- BEVANEC (NCT02820857)
- Testing
- Folfiri-bevacizumab, Folfiri
- Where
- 26 sites in France
- Volunteers
- 153 people
- Sponsor
- Hospices Civils de Lyon
Colorectal Cancer
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer
This is a multi-center, single-arm study to investigate the efficacy and safety of liposomal irinotecan+5-FU/LV+ bevacizumab as second-line therapy in metastatic colorectal cancer in Chinese population.
- Trial name
- NCT06184698
- Testing
- liposomal irinotecan, 5-FU, LV
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Hebei Medical University Fourth Hospital
Sarcoma,Soft Tissue, Sarcoma
Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above.
- Conditions
- Sarcoma,Soft Tissue, Sarcoma, Sarcoma of Bone
- Trial name
- NCT06637007
- Testing
- Chidamide Tablets combined with AK112
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanxi Province Cancer Hospital
Neuroendocrine Carcinoma, Grade 3
Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes
Phase II study of avelumab in metastatic gastronetro-pancreatic (GEP) neuroendocrine carcinoma (NEC, WHO grade 3) as second-line treatment after failing to etoposide+cisplatin: integration of genomic analysis to identify…
- Trial name
- MS100070-0177 (NCT03147404)
- Testing
- Avelumab
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Samsung Medical Center
Advanced Colorectal Cancer
Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II Trial
The ONTOP study is a prospective, single-arm, open-label phase II clinical trial. A total of 32 patients with advanced MSS/pMMR colorectal cancer who have failed first-line treatment will receive second-line standard treatment…
- Trial name
- ONTOP (NCT07106034)
- Testing
- Ongericimab + Toripalimab + Bevacizumab + FOLFOX, Ongericimab + Toripalimab + Bevacizumab + FOLFIRI
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shanghai Pudong Hospital
Extensive-Stage Small Cell Lung Cancer
Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy
This phase II trial studies how well IBI308 combined with paclitaxel/albumin-bound paclitaxel work in treating participants with small cell lung cancer after failing to platinum-etoposide chemotherapy.
- Trial name
- NCT04056949
- Testing
- Paclitaxel/Albumin-Bound Paclitaxel, IBI308
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Junling Li
Waldenstrom Macroglobulinemia
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia.
- Trial name
- BRAWM (NCT04624906)
- Testing
- Acalabrutinib, Bendamustine, Rituximab
- Where
- 9 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Sunnybrook Health Sciences Centre
Colorectal Cancer
OPTIMOX1 in Chinese mCRC Patients
Previous OPTIMOX1 study investigated the use of oxaliplatin discontinuation and reintroduction in a novel stop-and-go strategy. Previously untreated patients were randomly assigned to either FOLFOX4 administered every 2 weeks…
- Trial name
- NCT01023633
- Testing
- Oxaliplatin, LV, 5-FU
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Nanjing Medical University
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
This phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib…
- Conditions
- Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01746836
- Testing
- Laboratory Biomarker Analysis, Ponatinib Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer
Topotecan in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087048
- Testing
- topotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.